Comparison of inflammatory markers in type 2 diabetic patients treated with empagliflozin, metformin, and sulfonylurea
Background and aims: The present study aimed to compare the levels of the inflammatory biomarkers of fibrinogen and high-sensitivity C-reactive protein (hs-CRP) among type 2 diabetic patients treated with empagliflozin and other hypoglycemic drugs. Methods: This cross-sectional study was performed o...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Shahrekord University of Medical Sciences
2023-10-01
|
| Series: | Journal of Shahrekord University of Medical Sciences |
| Subjects: | |
| Online Access: | https://j.skums.ac.ir/PDF/jskums-25-189.pdf |
| _version_ | 1797386272547799040 |
|---|---|
| author | Pegah Mohaghegh Mohammad Reza Rezvanfar Farideh Jalali-Mashayekhi Zahra Amerei Mohammad Hosseinzadeh |
| author_facet | Pegah Mohaghegh Mohammad Reza Rezvanfar Farideh Jalali-Mashayekhi Zahra Amerei Mohammad Hosseinzadeh |
| author_sort | Pegah Mohaghegh |
| collection | DOAJ |
| description | Background and aims: The present study aimed to compare the levels of the inflammatory biomarkers of fibrinogen and high-sensitivity C-reactive protein (hs-CRP) among type 2 diabetic patients treated with empagliflozin and other hypoglycemic drugs. Methods: This cross-sectional study was performed on 90 patients with type 2 diabetes (≥30 years) receiving empagliflozin, metformin, and sulfonylurea who were referred to the diabetes clinics affiliated with Arak University of Medical Sciences. After obtaining consent to participate in the study, the patients were categorized into the treatment groups of metformin, metformin+empagliflozin, or metformin+sulfonylurea, and their characteristics and hypoglycemic drugs were recorded in the information checklist. The data were analyzed in SPSS 16 statistical software. Results: The fibrinogen level was minimized in the metformin+empagliflozin group, although the three groups were not significantly different in this regard (P=0.382). Based on the results, the parameter was higher in the individuals with ischemic heart disease, while a lower level was found among those treated with a lipid-lowering agent. In terms of hs-CRP level, no statistically significant difference was observed among the three groups, although the metformin group had a lower level (P=0.522). Conclusion: The minimum fibrinogen and hs-CRP levels were related to the metformin+empagliflozin and metformin groups, respectively. Further, several factors such as comorbidities and other consumed drugs could affect the concentration of inflammatory factors. Thus, it is suggested that clinical trials should be conducted in this respect. |
| first_indexed | 2024-03-08T22:07:56Z |
| format | Article |
| id | doaj.art-e014183f9c6345958367fdc2594a5a70 |
| institution | Directory Open Access Journal |
| issn | 2717-0071 |
| language | English |
| last_indexed | 2024-03-08T22:07:56Z |
| publishDate | 2023-10-01 |
| publisher | Shahrekord University of Medical Sciences |
| record_format | Article |
| series | Journal of Shahrekord University of Medical Sciences |
| spelling | doaj.art-e014183f9c6345958367fdc2594a5a702023-12-19T08:14:34ZengShahrekord University of Medical SciencesJournal of Shahrekord University of Medical Sciences2717-00712023-10-0125418919310.34172/jsums.794jskums-794Comparison of inflammatory markers in type 2 diabetic patients treated with empagliflozin, metformin, and sulfonylureaPegah Mohaghegh0Mohammad Reza Rezvanfar1Farideh Jalali-Mashayekhi2Zahra Amerei3Mohammad Hosseinzadeh4Department of Community Medicine, School of Medicine, Arak University of Medical Sciences, Arak, IranDepartment of Internal Medicine, School of Medicine, Amir-Almomenin Hospital, Arak University of Medical Sciences, Arak, IranDepartment of Biochemistry and Genetic, School of Medicine, Arak University of Medical Sciences, Arak, IranStudents Research Committee, Arak University of Medical Sciences, Arak, IranDepartment of Biochemistry and Genetic, School of Medicine, Arak University of Medical Sciences, Arak, IranBackground and aims: The present study aimed to compare the levels of the inflammatory biomarkers of fibrinogen and high-sensitivity C-reactive protein (hs-CRP) among type 2 diabetic patients treated with empagliflozin and other hypoglycemic drugs. Methods: This cross-sectional study was performed on 90 patients with type 2 diabetes (≥30 years) receiving empagliflozin, metformin, and sulfonylurea who were referred to the diabetes clinics affiliated with Arak University of Medical Sciences. After obtaining consent to participate in the study, the patients were categorized into the treatment groups of metformin, metformin+empagliflozin, or metformin+sulfonylurea, and their characteristics and hypoglycemic drugs were recorded in the information checklist. The data were analyzed in SPSS 16 statistical software. Results: The fibrinogen level was minimized in the metformin+empagliflozin group, although the three groups were not significantly different in this regard (P=0.382). Based on the results, the parameter was higher in the individuals with ischemic heart disease, while a lower level was found among those treated with a lipid-lowering agent. In terms of hs-CRP level, no statistically significant difference was observed among the three groups, although the metformin group had a lower level (P=0.522). Conclusion: The minimum fibrinogen and hs-CRP levels were related to the metformin+empagliflozin and metformin groups, respectively. Further, several factors such as comorbidities and other consumed drugs could affect the concentration of inflammatory factors. Thus, it is suggested that clinical trials should be conducted in this respect.https://j.skums.ac.ir/PDF/jskums-25-189.pdfempagliflozinfibrinogenhigh-sensitivity c-reactive proteininflammatory factorssodium-dependent glucose cotransporter 2 inhibitortype 2 diabetes |
| spellingShingle | Pegah Mohaghegh Mohammad Reza Rezvanfar Farideh Jalali-Mashayekhi Zahra Amerei Mohammad Hosseinzadeh Comparison of inflammatory markers in type 2 diabetic patients treated with empagliflozin, metformin, and sulfonylurea Journal of Shahrekord University of Medical Sciences empagliflozin fibrinogen high-sensitivity c-reactive protein inflammatory factors sodium-dependent glucose cotransporter 2 inhibitor type 2 diabetes |
| title | Comparison of inflammatory markers in type 2 diabetic patients treated with empagliflozin, metformin, and sulfonylurea |
| title_full | Comparison of inflammatory markers in type 2 diabetic patients treated with empagliflozin, metformin, and sulfonylurea |
| title_fullStr | Comparison of inflammatory markers in type 2 diabetic patients treated with empagliflozin, metformin, and sulfonylurea |
| title_full_unstemmed | Comparison of inflammatory markers in type 2 diabetic patients treated with empagliflozin, metformin, and sulfonylurea |
| title_short | Comparison of inflammatory markers in type 2 diabetic patients treated with empagliflozin, metformin, and sulfonylurea |
| title_sort | comparison of inflammatory markers in type 2 diabetic patients treated with empagliflozin metformin and sulfonylurea |
| topic | empagliflozin fibrinogen high-sensitivity c-reactive protein inflammatory factors sodium-dependent glucose cotransporter 2 inhibitor type 2 diabetes |
| url | https://j.skums.ac.ir/PDF/jskums-25-189.pdf |
| work_keys_str_mv | AT pegahmohaghegh comparisonofinflammatorymarkersintype2diabeticpatientstreatedwithempagliflozinmetforminandsulfonylurea AT mohammadrezarezvanfar comparisonofinflammatorymarkersintype2diabeticpatientstreatedwithempagliflozinmetforminandsulfonylurea AT faridehjalalimashayekhi comparisonofinflammatorymarkersintype2diabeticpatientstreatedwithempagliflozinmetforminandsulfonylurea AT zahraamerei comparisonofinflammatorymarkersintype2diabeticpatientstreatedwithempagliflozinmetforminandsulfonylurea AT mohammadhosseinzadeh comparisonofinflammatorymarkersintype2diabeticpatientstreatedwithempagliflozinmetforminandsulfonylurea |